/주식/ICCM
ICCM

ICCM

USD

IceCure Medical Ltd. Ordinary Shares

$0.728+0.000 (0.069%)

실시간 가격

Healthcare
의료 기기
이스라엘

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$0.728

고가

$0.740

저가

$0.714

거래량

0.13M

기업 기본 정보

시가총액

50.2M

산업

의료 기기

국가

Israel

거래 통계

평균 거래량

1.68M

거래소

NCM

통화

USD

52주 범위

저가 $0.534현재가 $0.728고가 $1.66

관련 뉴스

PR Newswire

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

더 보기
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical with a Buy and raises the price target from $2 to $2.5.

더 보기
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
PR Newswire

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for...

더 보기
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
PR Newswire

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

더 보기
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above